Amoéba S.A. (EPA:ALMIB)

Market Cap	64.75M +48.3%
Revenue (ttm)	682.46K -25.2%
Net Income	-7.36M
EPS	-0.14
Shares Out	68.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	130,827
Average Volume	190,410
Open	0.9360
Previous Close	0.9350
Day's Range	0.9300 - 0.9450
52-Week Range	0.7480 - 1.4440
Beta	0.01
RSI	49.43
Earnings Date	Apr 17, 2026

About Amoéba

Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopathogenic microorganisms using the lysed. Amoéba S.A. was incorporated in 2010 and is based in Chassieu, France.

• Industry: Agricultural Inputs
• Sector: Materials
• Founded: 2010
• Employees: 20
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALMIB

Financial Performance

In 2024, Amoéba's revenue was 601,600, a decrease of -9.44% compared to the previous year's 664,310. Losses were -6.59 million, -53.90% less than in 2023.